Brad Sippy is the founder of Tremeau Pharmaceuticals. Tremeau Pharmaceuticals has raised $59M in total funding. Latest round: Other. Based in Cambridge, US.
Brad Sippy is the CEO and co-founder of Tremeau Pharmaceuticals, a company established in 2016 in Cambridge, MA. The company is dedicated to developing non-opioid pain therapies for chronic pain conditions. Tremeau Pharmaceuticals was acquired by Gurnet Point Capital in a buyout deal in January 2019 for USD 59.3 million. Sippy's background includes prior ventures in the pharmaceutical industry.
Full founder directory · Investor directory · Company funding database · Fundraising library